Techniques in Vascular & Interventional Radiology
Volume 9, Issue 3 , Pages 125-132 , September 2006

Assessment of Tumor Response on MR Imaging After Locoregional Therapy

  • Josephina A. Vossen, MD

      Affiliations

    • J.A.V. and M.B. contributed equally to this work.
    • ,
  • Manon Buijs, MD

      Affiliations

    • J.A.V. and M.B. contributed equally to this work.
    • ,
  • Ihab R. Kamel, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ihab R. Kamel, MD, PhD, Russell H. Morgan Department of Radiology and Radiological Sciences, Division of Vascular and Interventional Radiology, 600 North Wolfe Street, Room 100, Baltimore, MD 21287.

References 

  1. Dodd GD, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: At the threshold of a major breakthrough. Radiographics. 2000;20:9–27
  2. Goldberg SN, Ahmed M. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Clin Gastroenterol. 2002;35(suppl 2):S115–S129
  3. Bartolozzi C, Lencioni R, Caramella D, et al. Hepatocellular carcinoma: CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection. Radiology. 1994;191:123–128
  4. Lencioni R, Caramella D, Bartolozzi C. Hepatocellular carcinoma: Use of color Doppler US to evaluate response to treatment with percutaneous ethanol injection. Radiology. 1995;194:113–118
  5. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  6. Therasse P, Arbuck SG, Eisenhauer EA, et al. European Organization for Research and Treatment of Cancer National Cancer Institute of the United States National Cancer Institute of Canada New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216
  7. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24:3245–3251
  8. Kamel IR, Bluemke DA. Magnetic resonance imaging of the liver: Assessing response to treatment. Top Magn Reson Imaging. 2002;13:191–200
  9. Bruix J, Sherman M, Llovet JM, et al. European Association for the Study of the Liver Clinical management of hepatocellular carcinoma (Conclusions of the Barcelona-2000 EASL conference). J Hepatol. 2001;35:421–430
  10. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  11. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: Diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology. 2006;239:122–130
  12. Law M, Yang S, Wang H, et al. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989–1998
  13. Yeung DK, Cheung HS, Tse GM. Human breast lesions: Characterization with contrast-enhanced in vivo proton MR spectroscopy—initial results. Radiology. 2001;220:40–46
  14. Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer. 2001;84:1016–1022
  15. Longo R, Ricci C, Masutti F, et al. Fatty infiltration of the liver (Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography). Invest Radiol. 1993;28:297–302
  16. Chen CY, Li CW, Kuo YT, et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: Choline levels and MR diffusion constants—initial experience. Radiology. 2006;239:448–456
  17. Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology. 2000;217:331–345
  18. Elton M. [Forensic psychiatrists must be more in agreement on the evaluation of juvenile delinquents]. Lakartidningen. 1991;88:2668
  19. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A. 2005;102:5524–5529
  20. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia. 2006;8:259–267
  21. Ni H, Kavcic V, Zhu T, et al. Effects of number of diffusion gradient directions on derived diffusion tensor imaging indices in human brain. AJNR Am J Neuroradiol. 2006;27:1776–1781
  22. Moseley ME, Cohen Y, Kucharczyk J, et al. Diffusion-weighted MR imaging of anisotropic water diffusion in cat central nervous system. Radiology. 1990;176:439–445
  23. Taouli B, Vilgrain V, Dumont E, et al. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: Prospective study in 66 patients. Radiology. 2003;226:71–78
  24. Yamada I, Aung W, Himeno Y, et al. Diffusion coefficients in abdominal organs and hepatic lesions: Evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology. 1999;210:617–623
  25. Lencioni R, Cioni D, Bartolozzi C. Percutaneous radiofrequency thermal ablation of liver malignancies: Techniques, indications, imaging findings, and clinical results. Abdom Imaging. 2001;26:345–360
  26. Sironi S, Livraghi T, Meloni F, et al. Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up. AJR Am J Roentgenol. 1999;173:1225–1229
  27. Goldberg SN, Gazelle GS, Dawson SL, et al. Tissue ablation with radiofrequency using multiprobe arrays. Acad Radiol. 1995;2:670–674
  28. Goldberg SN, Hahn PF, Tanabe KK, et al. Percutaneous radiofrequency tissue ablation: Does perfusion-mediated tissue cooling limit coagulation necrosis?. J Vasc Interv Radiol. 1998;9(Pt 1):101–111
  29. Curley SA, Marra P, Beaty K, et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg. 2004;239:450–458
  30. Horkan C, Ahmed M, Liu Z, et al. Radiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model. J Vasc Interv Radiol. 2004;15:269–274
  31. Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210:655–661
  32. Bartolozzi C, Crocetti L, Cioni D, et al. Assessment of therapeutic effect of liver tumor ablation procedures. Hepatogastroenterology. 2001;48:352–358
  33. Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol. 1998;170:1015–1022
  34. Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: Comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology. 2002;223:331–337
  35. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients. Ann Surg. 1999;230:1–8
  36. Lou CY, Feng YM, Qian AR, et al. Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98. World J Gastroenterol. 2004;10:1462–1465
  37. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006;17:505–512
  38. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–156
  39. Lin DY, Liaw YF, Lee TY, et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Gastroenterology. 1988;94:453–456
  40. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990;11:181–184
  41. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256–1261
  42. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology. 1998;27:1578–1583
  43. De Santis M, Alborino S, Tartoni PL, et al. Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. Eur Radiol. 1997;7:10–16
  44. Ito K, Honjo K, Fujita T, et al. Therapeutic efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma: MRI and pathology. J Comput Assist Tomogr. 1995;19:198–203
  45. Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single institution. J Vasc Interv Radiol. 2005;16:353–361
  46. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  47. Carty NJ, Foggitt A, Hamilton CR, et al. Patterns of clinical metastasis in breast cancer: An analysis of 100 patients. Eur J Surg Oncol. 1995;21:607–608
  48. Li XP, Meng ZQ, Guo WJ, et al. Treatment for liver metastases from breast cancer: Results and prognostic factors. World J Gastroenterol. 2005;11:3782–3787
  49. Lepage C, Bouvier AM, Phelip JM, et al. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut. 2004;53:549–553
  50. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11:1–18
  51. Norton JA. Surgical treatment of neuroendocrine metastases. Best Practice Res Clin Gastroenterol. 2005;19:577–583
  52. Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: Factors correlated with survival. Ann Oncol. 2005;16:1806–1810
  53. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096
  54. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The M.D. Anderson experience. Cancer J. 2003;9:261–267
  55. Roche A, Girish B, de BaÃr̈e T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13:136–140
  56. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83:2293–2301
  57. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer. 2005;104:1590–1602
  58. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(suppl 1):S194–S205
  59. Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: Preliminary results and clinical follow-up. J Nucl Med. 1994;35:1637–1644
  60. Sarfaraz M, Kennedy AS, Cao ZJ, et al. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys. 2003;30:199–203
  61. Buscombe JR, Padhy A. Treatment of hepatocellular carcinoma: A pivotal role for nuclear medicine?. Nucl Med Commun. 2001;22:119–120
  62. Deng J, Miller FH, Rhee TK, et al. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol. 2006;17:1195–1200

PII: S1089-2516(07)00017-0

doi: 10.1053/j.tvir.2007.02.004

Techniques in Vascular & Interventional Radiology
Volume 9, Issue 3 , Pages 125-132 , September 2006

Article Tools

* Image Usage & Resolution